Sugi Predict

Sugi Predict / Compounds / SCHEMBL1663229

SCHEMBL1663229

SCHEMBL1663229

Cn1nc(N)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRN P28799 3/20 0.56
▸ SORT1 Q99523 3/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ GABRP O00591 4/20 0.36
▸ GABRD O14764 4/20 0.36
▸ GABRA1 P14867 4/20 0.36
▸ GABRB1 P18505 4/20 0.36
▸ GABRG2 P18507 4/20 0.36
▸ GABRB3 P28472 4/20 0.36
▸ GABRA5 P31644 4/20 0.36
▸ GABRA3 P34903 4/20 0.36
▸ GABRA2 P47869 4/20 0.36
▸ GABRB2 P47870 4/20 0.36
▸ GABRA4 P48169 4/20 0.36
▸ GABRE P78334 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26241947 0.85 KDM4E (0.40) GRNSORT1KDM4EPKMGABRP
SCHEMBL3760854 0.83 KDM4E (0.39) GRNSORT1KDM4ECSF1RFGFR1
SCHEMBL2481607 0.80 ALDH1A1 (0.38) GRNSORT1KDM4EALDH1A1GAA
SCHEMBL17662694 0.79 KDM4E (0.36) GRNSORT1KDM4ECA12CA1
SCHEMBL22424005 0.79 BAZ2B (0.47) GRNSORT1KDM4EALDH1A1PHGDH
SCHEMBL24630337 0.79 KDM4E (0.36) GRNSORT1KDM4EALDH1A1GAA
SCHEMBL286598 0.79 CA12 (0.42) GRNSORT1KDM4ECA12CA1
SCHEMBL15182318 0.79 KDM4E (0.36) GRNSORT1KDM4E
SCHEMBL13557434 0.78 KDM4E (0.55) GRNSORT1KDM4ECA12CA1
Hydrochloric Acid SCHEMBL286597 0.77 CA12 (0.41) GRNSORT1KDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 — — US disclosed
CN-119421877-A Substituted heterocyclic compounds as HSET inhibitors 默克专利股份公司 2025-02-11 — — CN disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 — — EP disclosed
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X Design Therapeutics, Inc. 2023-09-14 — — US disclosed
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X Design Therapeutics, Inc. 2023-09-14 — — US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 — — US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 — — US disclosed
WO-2023131690-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2023-07-13 — — WO disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 — — US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 — — US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 — — US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 — — EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 — — WO disclosed
US-7105508-B1 Integrin receptors antagonists ABBOTT GMBH & CO. KG (DE) 2006-09-12 — — US disclosed
CN-1374960-A novel integrin receptor antagonists BASF AG (DE) 2002-10-16 — — CN disclosed
CN-1355811-A Integrain receptor antagaonists BASF AG (DE) 2002-06-26 — — CN disclosed
EP-1202988-A2 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2002-05-08 — — EP disclosed
EP-1173468-A1 INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2002-01-23 — — EP disclosed
WO-2001010847-A2 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2001-02-15 — — WO disclosed
WO-2000066618-A1 INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP GRN 7/4885SORT1 4303/4885KDM4E 1728/4885
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI GRN 1859/4885SORT1 4540/4885KDM4E 1053/4885
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 GRN 67/4885SORT1 2948/4885KDM4E 2603/4885
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X CYFIP2, TPX2, CYFIP1 GRN 105/4885SORT1 4143/4885KDM4E 1660/4885
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B GRN 3633/4885SORT1 3698/4885KDM4E 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.